Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
2.
Biol Neonate ; 78(4): 281-7, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11093007

ABSTRACT

The aim of this study was to investigate the effect of recombinant human erythropoietin (rHu-EPO) on oxygen affinity and adequate oxygen delivery to the tissues of stable premature infants. 36 very-low-birth-weight infants were randomly assigned to either receive rHu-EPO (200 units/kg every other day) or not, and both groups were supplemented with iron, folic acid and vitamin E. Arterial blood gases, oxygen saturation, complete blood counts, fetal haemoglobin, 2,3-diphosphoglycerate (2,3-DPG) and blood lactate were analysed weekly, from the 1st week till discharge. Patients in the two groups were comparable. There was a trend in increasing lactate values towards the 4th to 5th weeks of life, which did not reach statistical significance. There was no correlation between lactate values and the studied variables (pH, BE, oxygen saturation). In 35 transfusions, pre- and 24 h post-transfusion blood lactate status was studied. In 23 of them, a decrease in post-transfusion lactate was noticed, whilst an increased post-transfusion level was shown in 10 cases and no change in 2 cases. The mean pre-transfusion lactate value was significantly higher than the post-transfusion one (24.04 +/- 11.9 mg/dl before and 16.27 +/- 8.5 mg/dl after transfusion; p = 0.0025). In both groups there was a steady rise in 2,3-DPG concentration over the period of study, and the 2,3-DPG values at the end of our study were significantly increased in the rHu-EPO group (rHu-EPO 5.98 +/- 0.9, control 4.84 +/- 0.7; p = 0.04). In conclusion, the use of rHu-EPO did not affect blood lactate levels compared to the control group. Regarding oxygen affinity, it seems that rHu-EPO causes a shift of the oxy-haemoglobin dissociation curve to the right. This is a previously unreported effect of rHu-EPO and its clinical use may, thus, confer to preterm babies an added advantage.


Subject(s)
2,3-Diphosphoglycerate/blood , Anemia, Neonatal/drug therapy , Erythropoietin/therapeutic use , Infant, Premature , Infant, Very Low Birth Weight , Lactic Acid/blood , Anemia, Neonatal/therapy , Blood Transfusion , Fetal Hemoglobin/analysis , Humans , Infant, Newborn , Prospective Studies , Recombinant Proteins
3.
Acta Paediatr ; 89(12): 1493-4, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11195243

ABSTRACT

We report clinical and laboratory data from 32 children with benign acute childhood myositis (BACM), children who presented with calf tenderness and gait abnormality. Laboratory evidence of a viral infection was evident in 23 patients, while serum creatine phosphokinase was uniformly increased (558 to 6800 U/L). Twenty-five patients (78.1%) were given a diagnosis other than BACM by their general practitioner or paediatrician. All patients made a rapid recovery within one week. We conclude that BACM should be encountered among the main causes of sudden-onset gait abnormality in young children.


Subject(s)
Myositis/diagnosis , Myositis/physiopathology , Child , Child, Preschool , Creatine Kinase/blood , Diagnosis, Differential , Female , Humans , Male , Retrospective Studies
4.
Cytokine ; 11(1): 61-5, 1999 Jan.
Article in English | MEDLINE | ID: mdl-10080880

ABSTRACT

The in vivo influence of recombinant human erythropoietin (rhEpo) and iron on human neutrophil (PMN) antimicrobial function was assessed. A total of 21 preterm infants were randomized to receive either 200 U/kg/other day of rHuEPO+12 mg/kg/day of iron (EPO+high Fe, seven infants) or 200 U/kg/other day of rhEPO+4 mg/kg/day of iron (EPO+standard Fe, 9 infants) or 4 mg/kg/day of iron only (standard Fe, five infants). PMNs were isolated from blood of these infants 60+/-5 days after birth and from eight healthy adults. No differences between infants and adults were found in PMN random migration and chemotactic activity to N-formylmethionyl leucyl phenylalanine (FMLP), superoxide anion production in response to FMLP and phagocytosis of Staphylococcus aureus. In contrast, percentage phagocytosis was significantly lower in EPO+standard Fe as compared to both EPO+high Fe and standard Fe groups (P<0.01). This modest impairment of phagocytic activity of neonatal PMNs found in association with administration of rhEPO and standard iron may be related to consumption of iron during rhEPO-enhanced erythropoiesis.


Subject(s)
Anemia, Neonatal/drug therapy , Anemia, Neonatal/immunology , Erythropoietin/pharmacology , Neutrophils/drug effects , Neutrophils/immunology , Age Factors , Cell Count , Chemotaxis, Leukocyte/drug effects , Erythropoietin/therapeutic use , Humans , Infant, Newborn , Iron/pharmacology , Iron/therapeutic use , Phagocytosis/drug effects , Recombinant Proteins , Respiratory Burst/drug effects
5.
Pediatr Neurol ; 18(5): 420-4, 1998 May.
Article in English | MEDLINE | ID: mdl-9650683

ABSTRACT

Forty patients with beta-thalassemia major (BTM), between 11 and 19 years of age and maintained on long-term desferrioxamine (DFO) treatment, were examined by evoked potential and nerve conduction velocity studies to investigate a possible involvement of the auditory, visual, somatosensory, or peripheral nervous pathways. Pathologic findings in brainstem auditory-, visual-, and somatosensory-evoked potentials, and nerve conduction velocity studies were demonstrated in 25%, 15%, 7.5%, and 25% of the patients, respectively, whereas 15% demonstrated involvement of multiple neural pathways. Subclinical involvement of the auditory pathway was statistically associated with higher mean daily DFO dose and longer duration of DFO therapy, whereas abnormalities regarding the somatosensory pathways were related to older age, longer mean duration of DFO therapy, and lower serum copper levels. Involvement of the peripheral nervous system was related to lower serum copper levels. Multiple involvement of neural pathways was related to longer mean duration of DFO therapy. We conclude that risk factors related to long-term DFO treatment are only partly responsible for the subclinical involvement of neural pathways demonstrated in beta-thalassemia major patients.


Subject(s)
Brain Stem , Deferoxamine/adverse effects , Evoked Potentials/drug effects , Iron Chelating Agents/adverse effects , Neural Conduction/drug effects , beta-Thalassemia/drug therapy , Adolescent , Adult , Afferent Pathways/drug effects , Afferent Pathways/physiopathology , Age Factors , Brain Stem/drug effects , Brain Stem/physiopathology , Child , Copper/blood , Dose-Response Relationship, Drug , Evoked Potentials, Auditory, Brain Stem/drug effects , Evoked Potentials, Somatosensory/drug effects , Evoked Potentials, Visual/drug effects , Female , Humans , Logistic Models , Male , Sural Nerve/drug effects , Sural Nerve/physiopathology , Time Factors , beta-Thalassemia/blood , beta-Thalassemia/physiopathology , beta-Thalassemia/surgery
6.
J Exp Clin Cancer Res ; 16(2): 163-70, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9261742

ABSTRACT

The responsiveness of bone marrow erythroid progenitors (CFU-E and BFU-E) to various concentrations of recombinant human erythropoietin (rh-Epo) (2,5,20,40,100,200 and 500 U/ml) was investigated in vitro in 18 patients with B-chronic lymphocytic leukemia to assess the clinical usefulness of rh-Epo in this disease. Bone marrow mononuclear cells were cultured by methylcellulose methods for CFU-E and BFU-E assays. The B-chronic lymphocytic leukemia patients were divided into two groups according to the percentage of lymphocytes in the bone marrow (under 70% and over 70%). Among the patients with few lymphocytes, more than one third demonstrated some degree of response to rh-Epo. Among the patients with a high percentage of lymphocytes in the bone marrow, some revealed no response to rh-Epo, but there were patients who showed a good response to rh-Epo. Because erythroid progenitors from B-chronic lymphocytic leukemia appeared sensitive to rh-Epo in vitro, we propose that high doses of this drug may be clinically effective in some patients with this disease, regardless of the degree of lymphocytic inflitration of the bone marrow.


Subject(s)
Bone Marrow Cells , Bone Marrow/drug effects , Erythroid Precursor Cells/drug effects , Erythropoietin/pharmacology , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Aged , Dose-Response Relationship, Drug , Erythropoietin/blood , Female , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/blood , Male , Middle Aged , Recombinant Proteins/pharmacology
8.
Am J Perinatol ; 13(2): 85-7, 1996 Feb.
Article in English | MEDLINE | ID: mdl-8672191

ABSTRACT

Umbilical cord blood erythropoietin levels and hematocrit are significantly higher in smoking mothers than those nonsmoking ones. In addition, the incidence of newborns with low birthweight is higher in women who smoke. We conclude that in addition to other parameters, cord blood erythropoietin might be used as a valuable indicator of fetal distress in smokers.


Subject(s)
Erythropoietin/blood , Fetal Blood/chemistry , Fetal Distress/blood , Pregnancy Complications/etiology , Smoking/adverse effects , Adult , Case-Control Studies , Female , Fetal Distress/diagnosis , Fetal Distress/etiology , Hematocrit , Humans , Infant, Newborn , Male , Pregnancy , Pregnancy Complications/diagnosis
9.
J Pediatr ; 127(2): 291-7, 1995 Aug.
Article in English | MEDLINE | ID: mdl-7636658

ABSTRACT

OBJECTIVE: Treatment with recombinant human erythropoietin (rHuEPO) stimulates erythropoiesis and reduces the need for transfusions in hospitalized preterm infants. The aim of our study was to follow very low birth weight infants after the initial 6 weeks of rHuEPO treatment. DESIGN AND METHODS: We randomly assigned 97 very low birth weight infants with a gestational age of 31 weeks or less and birth weight of 1500 gm or less to receive rHuEPO, 300 units/kg per week (erythropoietin (EPO) 300, n = 33), rHuEPO, 750 units/kg per week (EPO 750; n = 28), or no treatment (control, n = 36). The rHuEPO was administered from the first week of life for 6 weeks. After EPO therapy was discontinued, 75 neonates were followed weekly until discharge and at 3, 6, and 12 months of age. RESULTS: Mean numbers (+/- SD) of packed erythrocyte transfusions per patient from the time rHuEPO therapy was discontinued until discharge were 0.38 +/- 0.64 (EPO 300), 0.23 +/- 0.52 (EPO 750), 0.9 +/- 1.1 (control) (p < 0.05 in both EPO groups vs control). Mean reticulocyte counts at the sixth week were 6% +/- 2.2% (EPO 300), 6.9% +/- 2.2% (EPO 750), and 3.1% +/- 2.6% (control) in the three groups (p < 0.01 in both EPO groups vs control), and at the eighth week were 4.7% +/- 2.8% (EPO 300), 5.4% +/- 2.7% (EPO 750), and 2.6% +/- 2.2% (control) (p < 0.01 in both EPO groups vs control). Serum ferritin levels were significantly higher at the sixth week, and the percentage of hemoglobin F was significantly lower at 6, 8, and 10 weeks in the control group versus EPO groups. At 3, 6, and 12 months of age, there were no differences in reticulocytes, ferritin, HbF, and growth among groups. CONCLUSION: Preterm infants who received rHuEPO had a normal pattern of erythropoiesis after the drug was discontinued. These data provide strong evidence that the anemia of prematurity is the result of a transient developmental abnormality in EPO production.


Subject(s)
Anemia, Neonatal/prevention & control , Erythropoietin/therapeutic use , Infant, Low Birth Weight , Infant, Premature, Diseases/prevention & control , Anemia, Neonatal/blood , Anemia, Neonatal/epidemiology , Drug Administration Schedule , Erythropoiesis/physiology , Erythropoietin/administration & dosage , Ferritins/blood , Follow-Up Studies , Hematocrit , Humans , Infant, Newborn , Infant, Premature, Diseases/blood , Infant, Premature, Diseases/epidemiology , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Time Factors , Treatment Outcome
10.
Am J Perinatol ; 11(6): 427-9, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7857436

ABSTRACT

In this study we determine the erythropoietin levels and hematocrit in 22 women with preterm labor, 21 with insulin-dependent diabetes, 22 with preeclampsia, and 20 with normal gestation. The erythropoietin level was higher in the preeclamptic group than in the diabetic group compared with the normal and premature groups. There were no hypoxic fetuses. From this study, we found that the mechanism of increased erythropoietin levels in neonates can be different from fetal hypoxia. Further studies are needed on this subject.


Subject(s)
Diabetes Mellitus, Type 1/blood , Erythropoietin/blood , Fetal Blood/chemistry , Obstetric Labor, Premature/blood , Pre-Eclampsia/blood , Pregnancy in Diabetics/blood , Adult , Birth Weight , Female , Humans , Pregnancy , Prospective Studies
12.
Pediatr Res ; 34(5): 675-9, 1993 Nov.
Article in English | MEDLINE | ID: mdl-8284109

ABSTRACT

To assess whether erythropoietin (EPO) treatment is safe and reduces the need for transfusion, we randomized 44 preterm infants to an EPO group and a comparable control (CON) group. EPO 150 U/kg was given s.c. twice weekly for 6 wk from the 1st wk of life. Hematologic parameters, transfusion requirements, and growth were followed during therapy and for 6 mo thereafter. To better assess in which neonates EPO treatment was effective, we classified retrospectively the EPO and CON groups into uncomplicated neonates (EPO A: n = 9, birth weight = 1247 +/- 126 g, gestational age = 29.8 +/- 1.5 wk; CON A: n = 7, birth weight = 1217 +/- 145 g, gestational age = 29.9 +/- 1.5 wk) and neonates requiring artificial ventilation (EPO B: n = 16, birth weight = 1169 +/- 249 g, gestational age = 28.1 +/- 2 wk; CON B: n = 12, birth weight = 1173 +/- 215 g, gestational age = 28.3 +/- 2 wk). There were significant differences in reticulocytes between both uncomplicated and ventilated neonates in the EPO group compared with respective control groups. However, the need for transfusion was significantly less in the uncomplicated EPO group (EPO A: 0.44 +/- 0.73 versus CON A: 1.28 +/- 0.75, p < 0.05) but not in the neonates on ventilation (EPO B: 8.25 +/- 5 versus CON B: 7.75 +/- 3.7). In conclusion, early EPO administration reduces the need for transfusion in uncomplicated premature neonates.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Anemia, Neonatal/prevention & control , Erythropoietin/pharmacology , Age Factors , Anemia, Neonatal/blood , Anemia, Neonatal/therapy , Blood Transfusion , Erythropoietin/blood , Ferritins/blood , Humans , Infant , Infant, Newborn , Infant, Premature , Recombinant Proteins/pharmacology , Reticulocyte Count
13.
Haematologia (Budap) ; 24(2): 63-70, 1991.
Article in English | MEDLINE | ID: mdl-1816056

ABSTRACT

The capacity of bone marrow and peripheral blood cells to stimulate colony formation by normal granulocyte-macrophage progenitor cells (CFU-GM) was investigated in two patients with severe congenital neutropenia using soft agar-gel culture techniques. In both patients, monocyte/macrophage-derived colony stimulating activity (GM-CSA) in conditioned medium was found to be significantly decreased compared to the control. Furthermore, the capacity of patients' unfractionated peripheral blood leukocytes to stimulate normal CFU-GM in overlayers, was also found significantly decreased. In contrast, the number of bone marrow and peripheral blood CFU-GM was within the normal range in both patients. Patients' CFU-GM showed a normal pattern of in vitro differentiation when they were stimulated by exogenous GM-CSA. These data indicate that in some cases of severe congenital neutropenia, monocyte/macrophage-derived GM-CSA may be impaired. Whether this abnormality plays some role in the regulation of granulopoiesis in these patients is unclear.


Subject(s)
Agranulocytosis/etiology , Bone Marrow/metabolism , Granulocyte-Macrophage Colony-Stimulating Factor/biosynthesis , Monocytes/metabolism , Neutropenia/metabolism , Agranulocytosis/blood , Cell Separation , Child, Preschool , Female , Humans , Infant , Male , Neutropenia/congenital
SELECTION OF CITATIONS
SEARCH DETAIL
...